Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pumitamig - BioNTech

Next Previous
Drug Profile

Pumitamig - BioNTech

Alternative Names: BMS-986545; BNT-327; PM-8002

Latest Information Update: 04 Aug 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Biotheus
  • Developer BioNTech; Biotheus; Bristol-Myers Squibb; Duality Biologics; Genmab
  • Class Antineoplastics; Bispecific antibodies; Immunotherapies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; B7-H1 antigen inhibitors; T lymphocyte stimulants; Vascular endothelial growth factor A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Small cell lung cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Non-small cell lung cancer; Small cell lung cancer; Triple negative breast cancer
  • Phase II/III Adenocarcinoma; Colorectal cancer; Gastric cancer
  • Phase II Glioblastoma; Liver cancer; Malignant-mesothelioma; Neuroendocrine tumours; Solid tumours
  • Phase I/II HER2 positive breast cancer; Lung cancer; Renal cell carcinoma

Most Recent Events

  • 24 Jul 2026 Phase-II clinical trials in Non-small cell lung cancer (Combination therapy, First-line therapy, Late-stage disease, Metastatic disease) in USA (IV) (NCT07680764)
  • 22 Jul 2026 Phase-I/II clinical trials in Solid tumours (Inoperable/Unresectable, Late-stage disease, Metastatic disease, Combination therapy, Recurrent) in Belgium, Belgium, Germany, Italy, Australia, Spain, Turkey (IV) (NCT07070232)
  • 02 Jul 2026 Bristol-Myers Squibb plans a phase II trial for Non-small cell lung cancer (First-line therapy, Late-stage disease, Metastatic disease, Combination therapy) in USA, Argentina, Australia, Brazil, Chile, China, France, Germany, Italy, Romania, Spain and UK (IV) (NCT07680764)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top